Krishna Institute of Medical Sciences Limited has announced a conference call with analysts and investors to discuss its Q3FY26 financial results and business strategy. The healthcare provider informed stock exchanges about this engagement pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings conference call is scheduled for Saturday, February 7, 2026, at 10:30 am IST. IIFL Capital will host the session, providing a platform for management to interact with the investment community following the declaration of Q3FY26 financial results.

Management Participation

The conference call will feature senior leadership from Krishna Institute of Medical Sciences, ensuring comprehensive coverage of the company's performance and strategic direction.

Access Information

IIFL Capital has provided multiple access options for participants across different regions. The call offers both domestic and international dial-in numbers to accommodate global investors.

India Access Numbers:

• Universal Access: +91 22 6280 1259 / +91 22 7115 8160

International Toll-Free Numbers:

• USA: 1-866 746 2133
• UK: 0-808 101 1573
• Singapore: 800-101 2045
• Hong Kong: 800-964 448

Regulatory Compliance

The company has fulfilled its disclosure obligations by notifying both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) about the conference call. The communication was signed by Nagajayanthi J. R., Company Secretary & Compliance Officer, on February 2, 2026.

For additional information regarding the conference call, participants can contact IIFL Capital representatives Rahul Jeewani, Naman Bagrecha, or Vivek Pandey through the provided contact details.

Krishna Institute of Medical Sciences Limited has announced a postal ballot seeking shareholder approval for a material related party transaction involving loans up to ₹150.00 crores to its subsidiary KIMS Hospital Bengaluru Private Limited (KHBPL). The company issued the notice on January 2, 2026, with the voting period scheduled from January 3, 2026, to February 1, 2026.

Postal Ballot Timeline and Process

The company has established a comprehensive timeline for the postal ballot process, with all voting conducted through electronic means only.

Transaction Details and Financial Structure

The proposed transaction involves extending loans to KHBPL, an unlisted subsidiary where Krishna Institute of Medical Sciences holds 80.00% of the paid-up equity shares. The loan structure includes a 12% interest rate, representing approximately 400 basis points above the company's average return on investments.

Historical Transaction Analysis

The company has provided detailed information about previous transactions with KHBPL, demonstrating the ongoing financial support for the subsidiary's operations.

Previous Financial Year (FY 2024-25)

Current Financial Year (FY 2025-26, up to Q2)

Strategic Rationale and Business Impact

The proposed loan aims to support KHBPL's operational scaling in the Bengaluru healthcare market. KHBPL, being a recently operational subsidiary, requires funding for working capital and additional capital expenditure needs. The subsidiary reported a turnover of nil and a net loss of ₹8.70 crores in the previous financial year, with a net worth of ₹71.50 crores.

The transaction represents 4.94% of the company's annual consolidated turnover of ₹3,035.00 crores for FY 2024-25. The Audit Committee, comprising entirely of Independent Directors, approved the transaction on December 29, 2025, confirming it as an arm's length transaction in the ordinary course of business.

Regulatory Compliance and Approval Process

The transaction requires shareholder approval as it constitutes a material related party transaction under Regulation 23 of SEBI Listing Regulations. The company has appointed Mr. Krishna Rao Inturi of IKR & Associates as the Scrutinizer for conducting the postal ballot process. MUFG Intime India Private Limited will provide the e-voting platform for shareholders.

The funding will be sourced partly from internal accruals and partly from borrowings, with the company's current borrowing rate at approximately 8.15%. The proposed 12% lending rate provides a favorable margin for the company while supporting the subsidiary's growth requirements in the competitive Bengaluru healthcare market.